ASH 2025: Driving Innovation and Advocacy in Hematology

The American Society of Hematology (ASH) Annual Meeting at the end of 2025 in Orlando delivered a powerful message: the field is rapidly advancing science while concurrently amplifying its commitment to patient advocacy and accessible care. The congress itself was a grounding experience, defined by bold scientific discourse, purposeful exhibition engagement, and a clear call to action for the hematology community to champion research, inclusion, and patient well-being.

The pervasive spirit of the week underscored a pivotal moment for hematology, demonstrating a focus on pushing the boundaries of what’s possible—not just in discovery, but in ensuring these breakthroughs reach those who need them most. Amidst a landscape of groundbreaking data and strategic discussions, these key themes emerged.

Oncology Advances: Redefining Response and Durability

The overarching scientific narrative at ASH 2025 confirmed that hematologic oncology is moving beyond incremental gains, stress-testing the limits of response, durability, and increasingly, the prospect of cure.

In B-cell lymphomas, the conversation clearly evolved past first-generation CD19-only CAR-T therapies. A new wave of early clinical data showcased broader targeting strategies designed to mitigate relapse and antigen escape. Miltenyi Biomedicine presented pivotal data on zamto-cel, a next-generation CAR-T for relapsed or refractory large B-cell lymphoma. This "fresh" CAR-T significantly cut the vein-to-infusion time to just two weeks, aiming to preserve T-cell fitness and demonstrating a clear advantage in event free survival over standard chemotherapy.

Accessibility beyond specialist centers also surfaced as a critical theme. Kite unveiled early-phase data on Kite-636 and Kite-753, two next-generation CAR-T therapies for relapsed or refractory large B-cell lymphoma. Both programs demonstrated encouraging disease control with safety profiles suitable for outpatient use, indicating a shift towards "community readiness" rather than exclusive hospital-based delivery. Kite-753 specifically demonstrated preserved T-cell health, a factor linked to sustained responses.

Further advancements in B-cell lymphoma included the development of allogeneic "off-the-shelf" CAR-T therapies. Legend Biotech's dual anti-CD20/CD19 CAR-T, LUCAR-G39D, showed promising first-in-human results with encouraging safety and efficacy in B-cell non-Hodgkin lymphoma (B-NHL). Imugene’s Azer-cel also garnered attention as a potential first-in-class option for patients with diffuse large B-cell lymphoma who relapse after CAR-T treatment, with Phase 1b data showing high overall response rates and molecular remissions. Lastly, PMB-CT01 from PeproMene Bio, a BAFFR-targeting CAR-T, was highlighted as a potential solution for B-NHL and B-cell acute lymphoblastic leukemia patients whose disease has progressed on CD19 CAR-T or is CD19-negative. Interim Phase 1 data suggested BAFFR targeting could overcome antigen escape while maintaining durable activity and low toxicity. Collectively, these data point to a future where CAR-T therapies are not only more effective but also more widely accessible.

In multiple myeloma, next-generation BCMA-targeted CAR-T therapies continued to solidify their promise. Kite’s anitocabtagene autoleucel (anito-cel) reinforced its best-in-class potential in relapsed or refractory disease, with data showcasing deep and durable responses. Patients achieved a 96% overall response rate at 15.9 months, with cancer undetectable in 74% of patients. Early proof-of-concept data for in vivo CAR-T generation also captivated attendees, with Kelonia Therapeutics presenting KLN-1010, which aims to generate BCMA-targeted CAR-T cells directly within the patient. Preliminary data showed no detectable cancer one month after treatment in patients with relapsed and refractory multiple myeloma, indicating an exciting, albeit early, paradigm shift.

Shifting Paradigms: Beyond Traditional Chemotherapy

A clear signal from ASH 2025 was the shift in treatment for blood cancers away from traditional, chemotherapy-heavy approaches. Instead, regimens offering reduced toxicity and treatment burden are gaining prominence.

In acute myeloid leukemia, combinations like azacitidine plus venetoclax continued to demonstrate their efficacy, showing that intensive induction chemotherapy is no longer the sole effective option.

In acute myeloid leukemia, combinations like azacitidine plus venetoclax continued to demonstrate their efficacy, showing that intensive induction chemotherapy is no longer the sole effective option. Elsewhere, bispecific antibodies and targeted inhibitors, including agents such as epcoritamab, glofitamab, and next-generation BTK inhibitors, illustrated how immune-based strategies can achieve durable disease control while enabling patients to spend less time in hospital.

One of the most anticipated readouts came from the Phase 3 MajesTEC-3 trial, which investigated a combination of the bispecific antibody teclistamab (Tecvayli) and the CD38-targeting antibody daratumumab (Tec-Dara) against standard second-line multiple myeloma treatments. Patients receiving Tec-Dara were 83% more likely to be alive without their disease progressing after nearly three years, an outcome that surprised investigators and suggests this combination could establish a new standard of care earlier in the disease course.

Chronic lymphocytic leukemia (CLL) offered another compelling example of this evolution. The CLL17 study demonstrated that fixed-duration targeted therapies, particularly venetoclax-based combinations, achieved non-inferior progression-free survival compared with continuous treatment using ibrutinib. For many newly diagnosed patients, time-limited therapy is now emerging as a primary option, effectively reducing the burden of indefinite treatment while maintaining efficacy. Further reinforcing the shift away from chemotherapy, data on next-generation BTK inhibition, specifically pirtobrutinib in previously untreated CLL and small lymphocytic lymphoma, showed improved progression-free survival and a more favorable safety profile compared with bendamustine plus rituximab. This strengthens the case for targeted, chemo-free approaches earlier in the disease.

While cure remains the ultimate ambition, ASH 2025 showcased that progress also encompasses fewer side effects, shorter or finite treatment durations, and therapies that integrate more realistically into patients' lives.

These advancements highlight a broader re-evaluation of success in hematologic oncology. While cure remains the ultimate ambition, ASH 2025 showcased that progress also encompasses fewer side effects, shorter or finite treatment durations, and therapies that integrate more realistically into patients' lives.

Expanding Horizons: Progress in Non-Malignant Hematology

While oncology dominated much of the scientific discourse, ASH 2025 also recognized significant, albeit quieter, milestones in non-malignant hematologic conditions.

In SCD, ASH highlighted advancements but also the continued need to foster a more comprehensive understanding of the lived experience of individuals with SCD.

The meeting marked ten years of sustained progress in sickle cell disease (SCD). This anniversary served as a reminder of the substantial advancements made, not only in treating acute crises but also in fostering a more comprehensive understanding of the lived experience of individuals with SCD. Sessions delved into the full spectrum of sickle cell pain and the growing importance of real-world data in shaping day-to-day care beyond traditional clinical endpoints.

ASH also spotlighted advances in other non-malignant conditions. Notably, in immune thrombocytopenia (ITP), Phase 3 data indicated that ianalumab, targeting the BAFF receptor, could meaningfully extend disease control when added to eltrombopag, effectively delaying progression and maintaining safe platelet counts for longer durations. These developments underscore that progress in hematology extends beyond cancer, delivering equally profound impacts on patients' lives outside the oncology spotlight.

The meeting repeatedly highlighted the persistent gap between innovation and access, acknowledging that breakthroughs only hold true meaning if patients can effectively reach them.

Advocacy and Patient Access at the Forefront

ASH 2025 conveyed a clear commitment to champion science, research, inclusion, and patients. Advocacy was visibly and deliberately woven into the fabric of the meeting, serving as an explicit signal that diversity of people, perspectives, and experience is fundamental to progress in hematology.

The meeting repeatedly highlighted the persistent gap between innovation and access, acknowledging that breakthroughs only hold true meaning if patients can effectively reach them. For complex therapies like CAR-T, barriers are not solely financial; they also encompass logistical challenges involving travel, time, and support networks. Here, advocacy was framed as concrete action rather than mere aspiration: supporting science necessitated actively fighting for health systems that enable patients to access these critical innovations.

Experiential Innovation: Engaging with Science

The spirit of purpose and intent extended seamlessly onto the exhibition floor. The expansive spaces commanded by companies like Sanofi, Novartis, Johnson & Johnson, Pfizer, and others were characterized by a consistent message: science-led and human-centered. Storytelling emphasized purpose and education, measuring success in lives touched rather than simply products launched.

What distinguished this year's exhibition was an emphasis on immersive engagement with intent. Sanofi created a spatial oncology experience designed to pull visitors directly inside the science. Incyte’s heme arch offered delegates the opportunity to hear directly from MPN and GVHD experts. Novartis adopted a provocative approach with its "Great minds think unalike" theme, paired with a fully immersive MOA movie theatre for ianalumab, blending sound, visuals, and data for a deeper understanding. Elsewhere, BMS guided clinicians through the practical realities of navigating CAR-T care, while Lilly’s "Be the Spark" experience tied directly into its IGNITE campaign for pirtobrutinib. Across the hall, the experiences were meticulously designed to educate and foster connection.

The focus was unmistakably HCP-centric. While previous years might have leaned on patient-centered art, ASH 2025 invited clinicians to engage directly with mechanisms, evidence, and decision-making, effectively making the exhibition an extension of the scientific program. Delegates weren't just observing the future of hematology; they were actively immersed in it.

As the curtain closed on ASH 2025, the enduring takeaway is clear: the congress successfully married scientific rigor with a profound commitment to patients. It showcased a dynamic field where groundbreaking data is rapidly transforming treatments, while simultaneously advocating for the inclusion, diversity, and access to ensure these advancements benefit everyone. The meeting underscored that true progress in hematology is achieved when discovery is intrinsically linked with dedicated patient advocacy.

Better science, better lives: the meaningful progress that defined 2025

2025 proved again that science delivers most when it’s anchored in relatable human insight.

Read Article

Insight

ESMO 2025: When discovery meets humanity

From landmark breakthroughs to moments of humanity, ESMO’s golden anniversary showed progress in oncology is powered not just by discovery, but by connection.